Physician

Andreas Herbert Syllaba, DO

According to 2025 Medicare claims, Andreas Syllaba, DO (NPI: 1063500932) practices general practice in the Dayton-Kettering-Beavercreek, OH market, with the plurality of this provider's patient population coming from Montgomery, OH. This provider's primary affiliated billing organization is PAIN EVALUATION & MANAGEMENT CENTER OF OHIO, INC. (NPI: 1811940182; TIN: 31-1393573) and primary practice location at 45458-1838.

Syllaba's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 315 traditional Medicare patients, billed 2,283 HCPCS/CPT codes, and received $140,960 in Medicare payments. The top billing code was G0482 (Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms). Part D data shows 2,964 prescription claims across 438 beneficiaries totaling $239,041 in drug costs, led by Buprenorphine (Buprenorphine). 2023 DME data shows 11 claims. Open Payments data shows 33 records totaling $616. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $244,865 and ending at $140,960. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $236,254 and ending at $239,041. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	604	16,342	$244,865
2016	687	8,533	$242,700
2017	433	3,328	$90,715
2018	21	135	$11,863
2019	29	204	$16,624
2020	816	3,826	$224,891
2021	592	3,523	$231,063
2022	242	1,002	$88,071
2023	335	1,802	$139,341
2024	315	2,283	$140,960

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	354	1,857	$236,254
2016	297	1,701	$231,707
2017	198	814	$115,521
2018	38	287	$26,599
2019	41	522	$40,378
2020	331	2,206	$160,042
2021	194	2,372	$182,556
2022	391	1,361	$116,314
2023	415	2,448	$212,359
2024	438	2,964	$239,041

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	46	$1,053
2016	38	75	$13,463
2017	N/R	N/R	N/R
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	11	11	$12,813
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms	94	142	$193
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	214	680	$89
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	200	365	$63
80307	Testing for presence of drug, by chemistry analyzers	96	147	$59
J0665	Injection, bupivicaine, not otherwise specified, 0.5 mg	40	407	$0

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Buprenorphine	Buprenorphine	120	3,366	$40,477
Belbuca	Buprenorphine Hcl	37	1,110	$31,768
Xtampza Er	Oxycodone Myristate	43	1,260	$31,266
Nucynta	Tapentadol Hcl	20	550	$20,604
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	739	21,716	$20,350

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	33	$616	Collegium Pharmaceutical, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Andreas Herbert Syllaba, DO?

Tedicare shows public-source Medicare data for Andreas Herbert Syllaba, DO (NPI 1063500932), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Andreas Herbert Syllaba, DO have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Andreas Herbert Syllaba, DO?

Andreas Herbert Syllaba, DO is linked to PAIN EVALUATION & MANAGEMENT CENTER OF OHIO, INC. (billing NPI 1811940182) in the available physician profile data.

Does Andreas Herbert Syllaba, DO have Open Payments data?

Andreas Herbert Syllaba, DO has 33 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.